Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NovoCure Ltd Director's Dealing 2022

Apr 14, 2022

31949_dirs_2022-04-14_2173820c-1f21-4a34-a333-c8a46bc56aad.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2022-04-14

Reporting Person: Ben Arye Barak (General Counsel)

Holdings (Non-Derivative)

Security Shares Ownership
Ordinary Shares 4223 Direct
Restricted Share Units 299 Direct
Restricted Share Units 7605 Direct
Restricted Share Units 870 Direct
Restricted Share Units 464 Direct
Restricted Share Units 2016 Direct
Restricted Share Units 1381 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Options to Buy Ordinary Shares $83.3 2029-07-30 Ordinary Shares (780.0) Direct
Options to Buy Ordinary Shares $21.15 2028-02-26 Ordinary Shares (2851.0) Direct
Options to Buy Ordinary Shares $69.37 2030-03-02 Ordinary Shares (7990.0) Direct
Options to Buy Ordinary Shares $47.04 2029-03-21 Ordinary Shares (2432.0) Direct
Options to Buy Ordinary Shares $87.66 2032-03-31 Ordinary Shares (13131.0) Direct
Options to Buy Ordinary Shares $107.73 2031-11-01 Ordinary Shares (831.0) Direct
Options to Buy Ordinary Shares $80.59 2032-02-29 Ordinary Shares (3532.0) Direct
Options to Buy Ordinary Shares $153.09 2031-03-01 Ordinary Shares (2401.0) Direct

Footnotes

F1: Represents restricted share units that are scheduled to vest on July 30, 2022, subject to the reporting person's continued employment through such dates.

F2: Represents restricted share units that are scheduled to vest on April 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.

F3: Represents restricted share units that are scheduled to vest on March 2, 2023 and 2024, subject to the reporting person's continued employment through such dates.

F4: Represents restricted share units that are scheduled to vest on November 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.

F5: Represents restricted share units that are scheduled to vest on March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.

F6: Represents restricted share units that are scheduled to vest on March 3, 2023, subject to the reporting person's continued employment through such dates.

F7: Options to buy 780 ordinary shares will vest in equal installments on each of July 30, 2022 and 2023, subject to the reporting person's continued employment through such dates.

F8: Currently exercisable.

F9: Options to buy 7,990 ordinary shares, 3,996 shares of which are currently exercisable and the remainder vest in equal installments on each of March 3, 2023 and 2024, subject to the reporting person's continued employment through such dates.

F10: Options to buy 2,432 ordinary shares, 1,216 shares of which are currently exercisable and the remainder vest on March 22, 2023, subject to the reporting person's continued employment through such dates.

F11: Options to buy 13,131 ordinary shares will vest in equal installments on each of April 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.

F12: Options to buy 831 ordinary shares will vest in equal installments on each of November 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.

F13: Options to buy 3,532 ordinary shares will vest in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.

F14: Options to buy 2,401 ordinary shares, 601 shares of which are currently exercisable and the remainder vest in equal installments on each of March 2, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.